This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignees: Hanall Biopharma Co., Ltd., Immunovant Sciences Gmbh. Active years: 2024.
Company Filing History:
1 out of 27 
1 out of 1 Years Active: 2024
Title: Seungkook Park: Innovator in Antibody Stability
Introduction
Seungkook Park is a prominent inventor based in Seoul, South Korea. He has made significant contributions to the field of biotechnology, particularly in the development of antibodies with enhanced stability. His work is crucial for advancing treatments for autoimmune diseases.
Latest Patents
Seungkook Park holds a patent for an "Anti-FcRn antibody or antigen binding fragment thereof with improved stability." This patent describes an innovative anti-FcRn antibody that binds non-competitively with IgG, compared to the parent antibody, HL161AN. The improved stability of this antibody reduces the production rate of aggregates while maintaining its biological activity. This advancement is particularly beneficial for reducing pathogenic autoantibodies in the blood, making it a promising candidate for treating autoimmune diseases.
Career Highlights
Throughout his career, Seungkook Park has worked with notable companies in the biotechnology sector. He has been associated with Hanall Biopharma Co., Ltd. and Immunovant Sciences GmbH. His experience in these organizations has allowed him to refine his expertise in antibody development and stability.
Collaborations
Seungkook Park has collaborated with esteemed colleagues, including William Louis Macias and Su Liang. These partnerships have contributed to his innovative research and the successful development of his patented technologies.
Conclusion
Seungkook Park's contributions to antibody stability represent a significant advancement in biotechnology. His innovative work has the potential to improve treatments for autoimmune diseases, showcasing the importance of research and development in this field.